> Back to EJC

Recent editions

  • June 2016
    Key advances in clinical trials.
  • May 2016
    Mark Lemmon on the underlying biochemistry of cancer.
  • April 2016
    Roger Stupp on using alternating electric fields as treatment.
  • March 2016
    Charlotte Vrinten on public perception of deaths from cancer.
  • February 2016
    Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
  • December 2015/January 2016
    Nazneen Rahman on germline genetic screening in ovarian cancer.
  • November 2015
    Caroline Robert on new developments in immunotherapy.
  • October 2015
    Milena Sant on the latest results from the EUROCARE study.
  • September 2015
    The science behind the IARC code that could reduce cancer in Europe.
  • July/August 2015
    Thomas Helleday on an exciting new class of drug, MTH1 inhibitors.
  • June 2015
    Lesley Seymour and Jan Bogaerts on the future of RECIST.
  • May 2015
    Paul Workman on strategies for overcoming resistance to new drugs.
  • April 2015
    Highlights from the TAT Congress in Paris.
  • March 2015
    Christopher Wild on the exposome, a measure of environmental exposure.

> All 2015 Editions

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – November 2013

Loading EJC News Focus video

Highlights of European Cancer Congress

"Astonishing" results with immunotherapy in a range of hard to treat cancers were the highlight of the Congress (27 September – 1st October, 2013) for Martine Piccart (ESMO). For Vincenzo Valentini (ESTRO), it was the new perception that that local treatment with radiation therapy could have an impact on systemic disease. Graeme Poston (ESSO) picked out the training of young surgical oncologists, which may now last only 6,000 hours, compared with up to 40,000 hours for previous generations of surgeons. How can the profession ensure that they are safe?

In this month's EJC News Focus, Helen Saul meets the Presidents of various cancer societies, including Moshe Oren (EACR), Birgitte Grube (EONS) and Cornelis van de Velde (ECCO), and asks for their take-home messages from the European Cancer Congress.